The Technical Analyst
Innovation [IPIX]
Exchange: PNK Industry: Biotechnology
Innovation Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0021
America/New_York / 3 mai 2024 @ 15:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.079 mill |
| EPS: | -0.0100 |
| P/E: | -0.210 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 514.01 mill |
| Avg Daily Volume: | 0.546 mill |
| RATING 2024-05-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.210 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.210 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0025 (17.69%) $0.0004 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0009 - 0.0051 ( +/- 142.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-30 | Ehrlich Leo | Sell | 11 307 527 | Class B Common Stock |
| 2021-10-10 | Harness Jane A. | Buy | 500 000 | Stock Option |
| 2020-09-11 | Harness Jane A. | Buy | 58 394 | Class A Common Stock |
| 2019-09-01 | Harness Jane A. | Buy | 58 394 | Class A Common Stock |
| 2020-09-11 | Harness Jane A. | Sell | 21 606 | Class A Common Stock |
| INSIDER POWER |
|---|
| -100.00 |
| Last 91 transactions |
| Buy: 118 435 245 | Sell: 65 639 262 |
Forecast:
16:00 - $0.0021
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0021 (0.00% ) |
| Volume | 0.0211 mill |
| Avg. Vol. | 0.546 mill |
| % of Avg. Vol | 3.86 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IPIX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Latest Press Releases
2023-08-28 08:00:00 - Press Release
Innovation Pharmaceuticals Announces New Milestone At Beamed; On Track To File 510(k) Submission To Fda In Q2 2024
Wakefield, ma, aug. 28, 2023 (globe newswire) -- via newmediawire -- innovation pharmaceuticals (otcqb:ipix) (“the company”), a clinical stage biopharmaceutical company and minority stakeholder in bt beamed technologies (“beamed”), is pleased to provide shareholders with an update on recent progress in the development of beamed's groundbreaking stingray laser system (the “system”). beamed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations.
2021-06-18 09:30:00 - Press Release
Innovation Pharma Announces New Brilacidin Antiviral Research On Non-sars-cov-2 Endemic Viral Diseases To Be Presented At The 2021 Military Health System Research Symposium
Wakefield, mass., june 18, 2021 (globe newswire) -- innovation pharmaceuticals (otcqb:ipix) (“the company”), a clinical stage biopharmaceutical company, today announced that antiviral research related to brilacidin has been accepted for an oral presentation at the 2021 military health system research symposium (mhsrs), taking place august 23-26, 2021, at the gaylord palms resort and convention center, kissimmee, fl.
2021-05-27 10:00:00 - Press Release
Patient Enrollment Reaches 90 Percent In Innovation Pharmaceuticals Phase 2 Clinical Trial Of Brilacidin For Covid-19
Wakefield, mass., may 27, 2021 (globe newswire) -- innovation pharmaceuticals (otcqb:ipix) (“the company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the company's 120-patient, phase 2 clinical trial of brilacidin for covid-19 has reached 90 percent and that the company anticipates full enrollment to be completed in approximately two weeks.
2021-04-28 08:00:00 - Press Release
Innovation Pharma Surpasses 50 Percent Enrollment In Phase 2 Clinical Trial Of Brilacidin For Covid-19
Wakefield, mass., april 28, 2021 (globe newswire) -- innovation pharmaceuticals (otcqb:ipix) (“the company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled phase 2 clinical trial of brilacidin for treatment of moderate-to-severe covid-19 in hospitalized patients (see nct04784897).
2021-04-14 09:30:00 - Press Release
Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted In Biodefense And Infectious Diseases Covid-19 Presentation
Wakefield, mass., april 14, 2021 (globe newswire) -- innovation pharmaceuticals (otcqb:ipix) (“the company”), a clinical stage biopharmaceutical company, today announced that brilacidin, the company's defensin-mimetic drug candidate, was featured in the “mason science series: rising to the national and international covid-19 challenge,” a presentation of george mason university.
Latest News
2021-06-18 09:30:00 - GlobeNewsWire
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral research related to Brilacidin has been accepted for an Oral Presentation at the 2021 Military Health System Research Symposium (MHSRS), taking place August 23-26, 2021, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL.
2021-05-27 10:00:00 - GlobeNewsWire
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company's 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.
2021-04-28 08:00:00 - GlobeNewsWire
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
2021-04-14 09:30:00 - GlobeNewsWire
Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University.
2021-04-07 09:30:00 - GlobeNewsWire
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology's Annual Meeting
WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to Brilacidin, the Company's defensin-mimetic drug candidate, has been accepted for an Oral Presentation at the American Society of Virology's 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.
2021-04-05 07:30:00 - GlobeNewsWire
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitoring Committee (DMC) completed its scheduled review of interim safety data in the Company's randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
2021-03-10 07:30:00 - GlobeNewsWire
Innovation Pharma's COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learning (Artificial Intelligence) model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2, the virus responsible for COVID-19. Published in Bioinformatics, by Oxford University Press, the Machine Learning ranking is based on a compound's predicted ability, due to its physicochemical properties, to bind to coronavirus proteins and thus inhibit viral replication. The predictive framework used in this research was built by assessing the structure of the main proteins of almost 100 different viral organisms, making the model generalizable to multiple viruses, according to the study's authors.
2021-03-05 11:31:00 - GlobeNewsWire
Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma's Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participating in the Company's international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19.
2021-01-29 09:15:00 - GlobeNewsWire
Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinical trial of Brilacidin for treating COVID-19 is scheduled to begin next week.
2021-01-14 07:30:00 - GlobeNewsWire
Innovation Pharmaceuticals' Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month